Compare VanEck Semiconductor ETF (SMH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Twist Bioscience Corp — how do they compare? VanEck Semiconductor ETF trades at $603.37 (market cap $73.92B), while Twist Bioscience Corp trades at $162.26 (market cap $10.08B). The key difference: VanEck Semiconductor ETF is far larger — about 7.3× Twist Bioscience Corp's market cap, and VanEck Semiconductor ETF is more actively traded (11,050,892 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 101 Days and Twist Bioscience Corp for 27 Days on average.
| SMH | TWST | |
|---|---|---|
Market Cap | $73.92B | $10.08B |
Volume | 11,050,892 | 4,229,037 |
52-Week High | $668.91 | $205.00 |
52-Week Low | $325.10 | $25.45 |
Typical Hold Time | 101 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH (VanEck Semiconductor ETF) trades at $603.00, down 3.52% on the day, while maintaining a bullish technical signal with strong moving average support. The ETF has delivered exceptional returns, up approximately 69% year-to-date through September 30, 2026, significantly outperforming individual semiconductor leaders like Nvidia. Recent industry developments include AMD's $8.2 billion acquisition of World Labs, expanding AI capabilities, and positive semiconductor market outlooks from major financial institutions.
The semiconductor sector shows strong momentum with Bank of America projecting the global chip market to nearly double by 2030. However, concentration risk in top holdings and potential rotation to equal-weight alternatives present challenges. The ETF's 12% pullback from recent highs offers entry opportunity, though investors should monitor sector rotation trends and geopolitical trade dynamics affecting semiconductor supply chains.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
